Weber Barbara 4
4 · Tango Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Tango (TNGX) Exec Chair Barbara Weber Sells Shares, Receives RSUs
What Happened
- Barbara Weber, Executive Chair and Director of Tango Therapeutics (TNGX), had automatic sell-to-cover transactions and received equity awards. On Feb 3, 2026 she sold 30,519 shares in two open-market transactions (30,186 shares at a weighted avg $12.26 for $369,999; 333 shares at $12.90 for $4,295), totaling about $374,294. On Feb 2, 2026 she was granted/issued 37,522 restricted stock units (RSUs) and a derivative equity award recorded as 222,132 shares (total grants = 259,654 shares) at $0.00 acquisition price.
Key Details
- Transaction dates/prices: Grants on 2026-02-02; sales on 2026-02-03. Sales weighted averages: $12.26 (range $11.88–$12.875) and $12.90 (range $12.88–$12.91).
- Shares sold: 30,519 shares for ~$374,294 (reported as sales, code S). Shares acquired: 37,522 RSUs (code A) and 222,132 derivative shares (code A, derivative).
- Vesting/conditions: RSUs vest in full on Feb 1, 2027 subject to continued service (footnote F1). The derivative award has an option-like vesting schedule: 12 equal monthly installments beginning after Jan 1, 2026 (footnote F5).
- Tax withholding: The sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vesting (footnote F2), not discretionary market sales by the insider.
- Filing timeliness: Report covers period 2026-02-02 and was filed 2026-02-04 — this appears to be a timely Form 4 filing.
- Shares owned after transaction: Not specified in the provided filing excerpt.
Context
- Sales that are automatic to cover taxes (sell-to-cover) are routine and do not necessarily signal a change in insider sentiment. The awards (RSUs and derivative award) are subject to future vesting and service conditions; they are not immediately transferrable stock until vested.
Insider Transaction Report
Form 4
Weber Barbara
DirectorDirector, Executive Chair
Transactions
- Award
Common Stock
[F1]2026-02-02+37,522→ 1,659,773 total - Sale
Common Stock
[F2][F3]2026-02-03$12.26/sh−30,186$369,999→ 1,629,587 total - Sale
Common Stock
[F2][F4]2026-02-03$12.90/sh−333$4,295→ 1,629,254 total - Award
Stock Option (Right to Buy)
[F5]2026-02-02+222,132→ 222,132 totalExercise: $11.94Exp: 2036-02-02→ Common Stock (222,132 underlying)
Footnotes (5)
- [F1]These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date.
- [F2]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F4]Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F5]This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Signature
/s/ Daniella Beckman, as attorney-in-fact|2026-02-04